702 related articles for article (PubMed ID: 32031033)
21. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Brackman D; Eckert D; Menon R; Salem AH; Potluri J; Smith BD; Wei AH; Hayslip J; Miles D; Mensing S; Gopalakrishnan S; Zha J
Hematol Oncol; 2022 Apr; 40(2):269-279. PubMed ID: 35043428
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
24. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract][Full Text] [Related]
25. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia.
Aumann S; Shaulov A; Haran A; Gross Even-Zohar N; Vainstein V; Nachmias B
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142863
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
[TBL] [Abstract][Full Text] [Related]
27. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes.
Shimony S; Stone RM; Stahl M
Curr Opin Hematol; 2022 Mar; 29(2):63-73. PubMed ID: 34966123
[TBL] [Abstract][Full Text] [Related]
28. Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?
Foran JM
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101335. PubMed ID: 34865692
[TBL] [Abstract][Full Text] [Related]
29.
Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A
Front Immunol; 2024; 15():1386517. PubMed ID: 38812504
[TBL] [Abstract][Full Text] [Related]
30. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
Sharma P; Pollyea DA
Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
[TBL] [Abstract][Full Text] [Related]
31. [Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].
Hu Y; Jin J; Zhang Y; Hu JD; Li JM; Wei XD; Gao SJ; Zha JH; Jiang Q; Wu J; Mendes W; Wei AH; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):288-294. PubMed ID: 33979972
[No Abstract] [Full Text] [Related]
32. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Kadia TM; Reville PK; Wang X; Rausch CR; Borthakur G; Pemmaraju N; Daver NG; DiNardo CD; Sasaki K; Issa GC; Ohanian M; Montalban-Bravo G; Short NJ; Jain N; Ferrajoli A; Bhalla KN; Jabbour E; Takahashi K; Malla R; Quagliato K; Kanagal-Shamanna R; Popat UR; Andreeff M; Garcia-Manero G; Konopleva MY; Ravandi F; Kantarjian HM
J Clin Oncol; 2022 Nov; 40(33):3848-3857. PubMed ID: 35704787
[TBL] [Abstract][Full Text] [Related]
33. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.
Masarova L; DiNardo CD; Bose P; Pemmaraju N; Daver NG; Kadia TM; Chifotides HT; Zhou L; Borthakur G; Estrov Z; Konopleva M; Verstovsek S
Blood Adv; 2021 Apr; 5(8):2156-2164. PubMed ID: 33885751
[TBL] [Abstract][Full Text] [Related]
34. SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML.
Inguva A; Pollyea DA
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):805-811. PubMed ID: 34389272
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia.
Ball BJ; Koller PB; Pullarkat V
Curr Opin Oncol; 2022 Sep; 34(5):531-539. PubMed ID: 35855507
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia.
Rodríguez-Medina C; Stuckey R; Bilbao-Sieyro C; Gómez-Casares MT
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338698
[TBL] [Abstract][Full Text] [Related]
37. Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
Nachmias B; Aumann S; Haran A; Schimmer AD
Br J Haematol; 2024 Apr; 204(4):1146-1158. PubMed ID: 38296617
[TBL] [Abstract][Full Text] [Related]
38. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data.
Hoff FW; Patel PA; Belli AJ; Hansen E; Foss H; Schulte M; Wang CK; Madanat YF
Leuk Lymphoma; 2023 Jun; 64(6):1123-1128. PubMed ID: 37052347
[TBL] [Abstract][Full Text] [Related]
39. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
Maiti A; Rausch CR; Cortes JE; Pemmaraju N; Daver NG; Ravandi F; Garcia-Manero G; Borthakur G; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Kadia TM; Takahashi K; Yilmaz M; Jain N; Kornblau S; Montalban Bravo G; Sasaki K; Andreeff M; Bose P; Ferrajoli A; Issa GC; Jabbour EJ; Masarova L; Thompson PA; Wang S; Konoplev S; Pierce SA; Ning J; Qiao W; Welch JS; Kantarjian HM; DiNardo CD; Konopleva MY
Haematologica; 2021 Mar; 106(3):894-898. PubMed ID: 32499238
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
